How Xeljanz Suppresses the Immune System
Xeljanz (tofacitinib) is a Janus kinase (JAK) inhibitor that blocks JAK enzymes inside immune cells. These enzymes transmit signals from cytokines—proteins that trigger inflammation and immune activation. By inhibiting JAK1 and JAK3, Xeljanz reduces production of inflammatory cytokines like IL-2, IL-6, IL-12, and IL-23, dampening T-cell and B-cell activity, natural killer cell function, and overall immune response.[1][2]
This leads to fewer activated immune cells attacking the body's own tissues, which helps in autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.
Why It Increases Infection Risk
With suppressed cytokine signaling, the body mounts weaker defenses against pathogens. Clinical trials show higher rates of serious infections (e.g., pneumonia, herpes zoster, tuberculosis) compared to placebo—up to 4.3 cases per 100 patient-years versus 2.3.[1][3] It also raises risks of opportunistic infections like fungal or viral ones, prompting FDA black box warnings for infections, malignancies, and thrombosis.
Effects on Specific Immune Pathways
- Adaptive Immunity: Limits T-cell proliferation and differentiation, reducing antibody production and cytotoxic responses.
- Innate Immunity: Curbs macrophage and neutrophil activation, impairing early pathogen clearance.
- Interferon Response: Weakens type I interferon signaling, which can increase viral susceptibility but benefits interferon-driven diseases like lupus (under investigation).[2][4]
Xeljanz does not broadly deplete cells like biologics (e.g., rituximab); it modulates signaling intracellularly.
Does It Affect Vaccines or Live Vaccines?
Xeljanz impairs vaccine responses, especially to live vaccines, which are contraindicated due to infection risk. Non-live vaccines (e.g., influenza, pneumococcal) show reduced efficacy—antibody titers drop 20-50% in studies.[1][5] Update vaccinations before starting therapy.
Long-Term Immune Changes and Monitoring
Over years of use, patients may see persistent T-cell suppression without full recovery upon discontinuation, though effects wane within weeks.[2] Doctors monitor with blood tests for lymphopenia, elevated liver enzymes, and lipid changes. Higher doses (10 mg twice daily) amplify suppression more than 5 mg.[3]
Comparison to Other Immunosuppressants
Unlike TNF inhibitors (e.g., Humira), which target one cytokine, Xeljanz hits multiple pathways for broader effect but higher infection risk. Versus steroids, it avoids metabolic side effects but carries thrombosis warnings. In head-to-head trials, it matches biologics in efficacy with similar infection profiles.[4][6]
Sources
[1]: Xeljanz Prescribing Information (Pfizer)
[2]: Nature Reviews Rheumatology: JAK inhibitors mechanism
[3]: FDA Label Updates
[4]: New England Journal of Medicine: ORAL Surveillance Trial
[5]: Annals of the Rheumatic Diseases: Vaccine Response
[6]: DrugPatentWatch.com: Xeljanz Patents and Competitors